Novartis india

download Novartis india

of 17

Embed Size (px)

Transcript of Novartis india

R&D

ORGANISATIONAL CAPABILITIES OFPRESENTED BY:GUARAV DOSHITARIKA DUGESHARPARTH GANDHIHIMANSHU TRIPATHIVINAYAK INDULKAR

NOVARTIS INDIA Novartis has been in India since 1947.The Group operates in India through four entities namely Novartis India Limited, Novartis Healthcare Private Limited, Sandoz Private Limited and Chiron-Behring Vaccine Private Limited.In India Novartis has a presence in pharmaceuticals, generics (pharmaceutical products that are off patent), Vaccines, OTC (over-the-counter medicines), eye care.Mission :- Want to discover , develop, and successfully market innovative products to prevent and cure disease , to ease suffering and to enhance quality of lifeVision :- Want to provide share holder return that reflect outstanding performance and to adequately reward those who invest their money, time and idea in our company.RESEARCH & DEVELOPMENTNovartis Institute for Biomedical ResearchNIBR is the global research organization of Novartis. With more than 6000 scientists and physicians around the world, NIBR is focused on discovering new drugs that can change the practice of medicine.Increase in R&D spending from US $ 80 million in 2001 to 2.4 billion in 2013.

ContR&D efforts are guided by two principles:Do we understand the underlying mechanism or cause of the disease?Does this disease represent a significant unmet medical need in patients?Novartis is well known for innovation

Novartis has a long-established track record of leadership in pharmaceutical research.Also leverage this core R&D competence across other divisions, sharing research findings and knowledge throughout organization.Sandoz, the generics division of Novartis, is the world leader in biosimilars, oncology injectables, dermatology, ophthalmics, and anti-infectives that have lost patent protection. By 2018, patents are scheduled to expire on biologics with global sales of more than USD 100 billion and Sandoz is well-positioned to take full advantage of that opportunity. Flu and the emerging meningococcal franchise will be key growth drivers for the Vaccines Division. The division also has a broad pipeline of new vaccines under development.Marketing Related FactorVACCINES :-The Novartis influenza vaccines business is among the worlds largest producers of influenza vaccinesFlucelvax ,Flaud ,FluvirinRabipur from Novartis india contain Vaccines RabiesUsed in animal bites Cont.Sandoz (Generics)Sandoz, the generic pharmaceuticals division of Novartis, is a global industry leader, offering affordable, high-quality medicines. It is the third-largest division of Novartis, representing nearly 16% of the Groups total net sales.

ContOTC PRODUCT OF NOVARTIS Focus on self care brands for consumerOffering products like Otrivin (nasal spray)Voveran cream (analgesic cream)Marketing ContBUSINESS SEGMENTPRODUCT NAMESTHERAPEUTIC AREACOMMENT MARKET SHAREPHARMAVOVERANPAIN AND INFLAMMATOYRRANK 111.4 %OTRIVINNASAL SPRAYRANK 127.0 %MACALVITCALCIUM SUPPLIMENTRANK 36.9 %Marketing cntBUSINESS SEGMENTBRANDSTHERAPEUTIC AREACOMMENTSMARKET SHAREOTCTOTAL SANDOZ BRANDCALCIUM SUPLLEMENTRANK 214.5%GENERICFORISTALANTI HISTAMINICRANK 130 %ManufacturingNovartis india ltd has 4 manufacturing sites in india approved by the EU and USFDAKolshet:- Houses the sandos devellopment center and Anti TB formulation plant for global project.Turbhe:-dedicated cephaloshporins manufacturing site for API & FDF since 2001Kalwe :- oral solid dosage plant with capacity of 1 billion unites , expansion to 5 billion unites under wayMahad :- dedicated fermentation plant

Sales Segmental performancePharmaceutical Business(contribution 66% ) Sales :- Rs 1552.4mn Growth :- 13.1 %OTC Business (Contribution 18% ) Sales :- Rs 422.1 mn Growth :- 25.9 %Sales cont..Generic Business ( Contribution 5.7 % ) Sales :- 135mn Growth :- -4.2%Animal health business (Contribution 10.2%) Sales :- 238.8 mn Growth :- -3.3%Novartis operates in 140 countriesCompany having strong distribution channel of 20 c&f agents and approximately 250 stokist in india.To prevent counterfeiting,Novartis pays much attention to the distribution process and channels

VRIO ANALYSISTHANK YOU..!!!